Loading...

VOR VOR BIOPHARMA INC US FDA Inspections 8-K Filing

VR B

VR

VOR BIOPHARMA INC

(VOR)

2024 8-K

Show Summary

Show Summary

Equity Offerings

Workforce Reduction

Noncompliance with Listing ...

Management Change

Stock Option Repricing

Board Appointment

Private Placement

Clinical Data Update

CFO Appointment

Resignation and Appointment

Equity Incentive Plan Amend...

Appointment of Director

Clinical Update

Annual Meeting of Stockholders

Resignation of Director

Clinical Update

External Links:

Vor Biopharma Inc. announced updated clinical data from its Phase 1/2 VBP101 study showing promising results in patients with relapsed/refractory AML, including improved survival rates and positive FDA feedback on trial design.

AI Assistant

VOR BIOPHARMA INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.